Insider · CIK 0002091053
Janice Suzann Drew
Files at EVMN (Evommune, Inc.). First filing Jun 24, 2026, latest Jun 24, 2026.
In brief
Janice Suzann Drew files SEC Form 4 as officer at EVMN (Evommune, Inc.). Since Jun 24, 2026, Janice Suzann Drew has reported 0 open-market buys worth $0 and 1 open-market sell worth $453k, the latest filed on Jun 24, 2026.
A track record needs three past buys with six months of prices behind them; Janice Suzann Drew has 0, so none is measured yet.
The newest scored trade: sold $453k of EVMN on Jun 22, 2026, filed Jun 24, 2026, scored 17 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $453k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EVMN: Evommune, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 17Weak | Evommune, Inc. | $453k 20,000 shares | -23% | +50% from low-29% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 22, 2026 | EVMN EVOMMUNE, INC. | 20,000 0.06% of outstanding | $427k | Jun 22, 2026 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | EVMN Evommune, Inc. | MOption exercise Common Stock10b5-1 | +3,839 | $3.84 | $15k | 71,633 | Jun 24, 2026 |
| Jun 22, 2026 | EVMN Evommune, Inc. | MOption exercise Common Stock10b5-1 | +16,161 | $2.99 | $48k | 87,794 | Jun 24, 2026 |
| Jun 22, 2026 | EVMN Evommune, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $22.63 | $453k | 67,794 | Jun 24, 2026 |
| Jun 22, 2026 | EVMN Evommune, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -3,839 | $0.00 | $0 | 53,795 | Jun 24, 2026 |
| Jun 22, 2026 | EVMN Evommune, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -16,161 | $0.00 | $0 | 39,321 | Jun 24, 2026 |
| Apr 16, 2026 | EVMN Evommune, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +73,892 | $0.00 | $0 | 73,892 | Apr 17, 2026 |
| Dec 9, 2025 | EVMN Evommune, Inc. | FTax withholding Common Stock | -5,074 | $17.84 | $91k | 67,794 | Dec 11, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Common Stock | +1,587 | - | - | 72,868 | Nov 12, 2025 |
| Nov 7, 2025 | EVMN Evommune, Inc. | CConversion Series B Preferred Stockderivative | -12,500 | - | - | 0 | Nov 12, 2025 |
| Nov 5, 2025 | EVMN Evommune, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +231,274 | $0.00 | $0 | 231,274 | Nov 7, 2025 |
Questions about Janice Suzann Drew
Answered from the filings on this page, as of the latest one.
Is Janice Suzann Drew buying or selling?
In the last 12 months Janice Suzann Drew reported 0 open-market buys worth $0 and 1 open-market sell worth $453k on SEC Form 4; the latest was sold $453k of EVMN on Jun 22, 2026. Grants, option exercises and tax withholding are not counted.
How did Janice Suzann Drew's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Janice Suzann Drew has 0.
Where does Janice Suzann Drew file Form 4?
Janice Suzann Drew has filed Form 4 at EVMN (Evommune, Inc.) as Chief of Dev. Operations. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.